Marshall Wace LLP Makes New Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX)

Marshall Wace LLP acquired a new stake in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 67,733 shares of the company's stock, valued at approximately $1,180,000. Marshall Wace LLP owned 0.12% of Bicara Therapeutics at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Vanguard Group Inc. grew its position in shares of Bicara Therapeutics by 1,457.9% during the 4th quarter. Vanguard Group Inc. now owns 1,090,528 shares of the company's stock valued at $18,997,000 after acquiring an additional 1,020,528 shares during the period. Alliancebernstein L.P. increased its holdings in shares of Bicara Therapeutics by 16.0% in the 4th quarter. Alliancebernstein L.P. now owns 821,264 shares of the company's stock worth $14,306,000 after buying an additional 113,261 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Bicara Therapeutics by 859.4% in the 4th quarter. Geode Capital Management LLC now owns 466,642 shares of the company's stock worth $8,131,000 after purchasing an additional 418,003 shares during the period. Charles Schwab Investment Management Inc. purchased a new position in shares of Bicara Therapeutics during the 4th quarter worth about $2,731,000. Finally, Norges Bank purchased a new stake in Bicara Therapeutics in the fourth quarter worth $1,219,000.

Bicara Therapeutics Price Performance

Shares of NASDAQ BCAX traded down $0.21 during mid-day trading on Friday, reaching $14.50. 728,148 shares of the company traded hands, compared to its average volume of 480,490. The stock has a fifty day simple moving average of $12.94 and a 200-day simple moving average of $15.91. Bicara Therapeutics Inc. has a fifty-two week low of $8.91 and a fifty-two week high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.08). As a group, equities research analysts forecast that Bicara Therapeutics Inc. will post -2.59 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently commented on BCAX. Stifel Nicolaus set a $48.00 price objective on shares of Bicara Therapeutics in a research note on Thursday, March 27th. HC Wainwright reduced their price target on Bicara Therapeutics from $45.00 to $44.00 and set a "buy" rating for the company in a research report on Monday, April 7th. Wedbush reaffirmed an "outperform" rating and issued a $31.00 price target on shares of Bicara Therapeutics in a report on Thursday, March 27th. Cantor Fitzgerald restated an "overweight" rating and set a $13.01 price target on shares of Bicara Therapeutics in a research report on Thursday, March 13th. Finally, Wells Fargo & Company assumed coverage on shares of Bicara Therapeutics in a research note on Thursday, April 17th. They set an "underweight" rating and a $8.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $32.43.

Bicara Therapeutics Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.